Healthcare Services

Neuroblastoma Market Forecast Through 2030 Featuring Industry Drivers And Opportunities

June 2, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Growth In Market Value Is Anticipated For The Neuroblastoma Market Between 2026 And 2030?

The neuroblastoma market size has experienced considerable growth in recent years. It is anticipated to expand from $3.14 billion in 2025 to $3.32 billion in 2026, registering a compound annual growth rate (CAGR) of 5.8%. This historical growth can be ascribed to a higher incidence of pediatric neuroblastoma, the timely adoption of chemotherapy treatments, the progress in developing immunotherapy vaccines, improvements in clinical diagnosis capabilities, and heightened awareness of childhood cancer symptoms.

The neuroblastoma market is projected to experience substantial growth in the coming years, reaching $4.12 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.5%. This anticipated growth during the forecast period is primarily driven by an expansion in targeted therapy research, increased investment in cell therapy products, the growing use of precision oncology methods, the creation of novel pediatric immunotherapy solutions, and advancements in diagnostic imaging for earlier detection. Key trends anticipated during this period encompass the wider adoption of immunotherapy vaccines for pediatric cancer, the increasing application of targeted oral chemotherapy tablets, the escalating development of monoclonal antibody treatments, the broadening of cell therapy and regenerative oncology approaches, and a heightened emphasis on early diagnosis and symptom management.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20901&type=smp

What Are The Main Drivers Accelerating The Growth Of The Neuroblastoma Market?

The rising incidence of childhood cancer is anticipated to fuel the expansion of the neuroblastoma market moving forward. Childhood cancer encompasses a range of malignancies primarily affecting children and adolescents, frequently impacting organs such as the brain, blood, and bones, thereby necessitating specialized therapeutic approaches. The increased occurrence of childhood cancer is attributed to factors including improved diagnostic techniques, heightened awareness, environmental exposures, genetic predispositions, and progress in medical research. Neuroblastoma treatment provides focused therapies for childhood cancer, facilitating prompt and effective intervention that mitigates the risk of recurrence and enhances outcomes for young patients. For instance, in May 2024, according to the American Cancer Society, a US-based professional organization company, approximately 9,620 children under the age of 15 in the United States are projected to be diagnosed with cancer in 2024, an increase from 5,290 cases in 2023. Consequently, the growing incidence of childhood cancer is driving the growth of the neuroblastoma market.

Which Segment-Based Categories Are Covered In The Neuroblastoma Market?

The neuroblastoma market covered in this report is segmented –

1) By Product Type: Tablets, Vaccines, Other Product Types

2) By Treatment Type: Chemotherapy, Immunotherapy, Other Treatment Types

3) By Distribution Channel: Online, Offline

4) By End-User: Hospitals, Clinics

Subsegments:

1) By Tablets: Oral Chemotherapy Tablets, Targeted Therapy Tablets

2) By Vaccines: Immunotherapy Vaccines, Therapeutic Vaccines

3) By Other Product Types: Injectable Drugs, Monoclonal Antibodies, Cell Therapy Products

Which Trends Are Expected To Shape The Neuroblastoma Market?

Leading companies in the neuralgia treatment market are prioritizing the development of advanced solutions, such as peripheral nerve-targeted delivery systems, to enhance therapeutic accuracy, alleviate chronic neuropathic pain, and improve long-term patient outcomes. Peripheral nerve-targeted delivery systems are specialized therapeutic platforms that deliver analgesic or neuromodulatory agents directly to affected nerves, allowing for more precise modulation of pain signals while minimizing systemic exposure. For example, in April 2023, GlaxoSmithKline Pharmaceuticals Ltd., an India-based pharmaceutical company, introduced Shingrix in India. This product is the world’s first non-live and recombinant subunit vaccine, designed to prevent shingles and post-herpetic neuralgia in adults aged 50 years and older, administered intramuscularly in two doses. Shingrix combines the antigen glycoprotein E with the adjuvant system AS01B to generate a potent and lasting immunological response, which helps counteract the immune system’s decline with age. Clinical trials have shown it to be 97% effective in preventing shingles in adults and also effective in preventing post-herpetic neuralgia, a painful complication of shingles.

Which Industry Players Are Present In The Neuroblastoma Market?

Major companies operating in the neuroblastoma market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Sartorius AG, Recordati S.p.A, United Therapeutics Corporation, BeiGene Ltd., MacroGenics Inc., Y-mAbs Therapeutics Inc., RedHill Biopharma Ltd., Clarity Pharmaceuticals Ltd., EUSA Pharma (UK) Ltd., US WorldMeds LLC, Ascentage Pharma, Laboratorio Elea Phoenix S.A, Curis Inc., PersonGen BioTherapeutics (Suzhou) Co. Ltd., Essential Pharma S.A, Cellectar Biosciences Inc., Provectus Biopharmaceuticals Inc.

Access The Complete Neuroblastoma Market Report:

https://www.thebusinessresearchcompany.com/report/neuroblastoma-global-market-report

Which Region Commands The Largest Share Of The Neuroblastoma Market?

North America was the largest region in the neuroblastoma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuroblastoma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Neuroblastoma Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=20901&type=smp

Browse Through More Reports Similar to the Global Neuroblastoma Market 2026, By The Business Research Company

Fibromyalgia Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/fibromyalgia-treatment-global-market-report

Muscle Pain Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/muscle-pain-treatment-global-market-report

Migraine Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/migraine-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795